Background
==========

Tuberculosis (TB) and its multi- and extensively drug-resistant forms (M/XDR-TB) are a major global public health concern. The World Health Organization (WHO) estimates that 9.6 million people worldwide fell ill with TB in 2014, of those ca 480,000 cases with MDR-TB \[[@r1]\]. Where second-line drug susceptibility testing (DST) is available, (pre)XDR-TB is frequently detected \[[@r2],[@r3]\]. These patients have a high risk of death \[[@r3]\].

To control this infectious disease, it is key to understand and interrupt the spread of TB and M/XDR-TB. TB transmission can be traced by classic and by molecular epidemiological methods. Classic methods include contact and source case investigations based on patient interviews. Molecular methods examine the genetic relationship between the isolates of the *Mycobacterium tuberculosis* complex. Common genotyping methods include spacer oligonucleotide typing (spoligotyping) and 24-loci mycobacterial interspersed repetitive units variable number of tandem repeats (24-loci MIRU-VNTR) analysis, both targeting specific small parts of the genome. Whole genome sequencing (WGS) queries the entire mycobacterial genomic material. It has higher discriminatory power and may indicate the directionality and sequence of transmission events \[[@r4]-[@r7]\]. Moreover, WGS permits identification of genes and mutations that mediate drug resistance \[[@r8]-[@r11]\]. WGS has been employed to analyse and review TB outbreaks in different settings \[[@r5],[@r12],[@r13]\]. Recently, it has become increasingly affordable and routinely applicable \[[@r8],[@r14],[@r15]\].

Austria, Romania and Germany are European Union (EU) Member States with, respectively, TB notification rates of 6.8, 79.7 and 5.6 cases per 100,000 population, rather similar proportions of MDR-TB among new laboratory-confirmed TB cases with DST results of 4.8%, 6.4% and 3.1%, yet very different absolute numbers of detected MDR-TB cases with 20, 517 and 87 cases in 2014 \[[@r2]\].

None of the three countries has an area-wide integrated molecular surveillance for TB as established in the Netherlands \[[@r16]\], the United Kingdom (UK) \[[@r17]\] or the United States (US) \[[@r18]\]. However, the National Reference Laboratories (NRLs) for Mycobacteria in Austria and Germany systematically type M/XDR-TB isolates. Germany submits the results to the genotyping database of the European Centre for Disease Prevention and Control (ECDC) \[[@r19]\].

In March 2014, the Austrian NRL at the Austrian Agency for Health and Food Safety (AGES) detected a molecular cluster of five MDR-TB cases. The question arose whether MDR-TB transmission had occurred within Austria, which had never been observed before. Links to Romania and Germany prompted the three countries to investigate the MDR-TB cluster jointly within given legal contexts and with unchanged in-country responsibilities, with the aim of tracing the MDR-TB transmission.

Methods
=======

Collaboration
-------------

The investigation team consisted of the national TB contact points for WHO and ECDC or representatives acting on their behalf, the NRLs and the responsible local public health authorities in Austria, Romania and Germany. Collaboration was maintained by monthly telephone conferences from April to October 2014.

Case inclusion
--------------

Cases were included without restriction in time when the isolate, collected in any of the three countries and recorded in any typing databases by the NRLs, shared the same spoligotype and 24-loci MIRU-VNTR pattern as in the initial cluster detected in Austria in March 2014. Five MDR-TB cases from one administrative district in Romania were included based on epidemiological information in the absence of molecular typing data. No epidemiological links pointing to other districts in Romania were identified.

Drug susceptibility testing
---------------------------

Isolates were gained by culturing specimens in liquid (BACTEC MGIT 960, Becton Dickinson Diagnostic Systems, Sparks, US) and on solid Löwenstein-Jensen (LJ) media.

In Austria and Germany, DST was done using the Mycobacteria Growth Indicator Tube (MGIT) system with BACTEC MGIT 960 growth supplement for DST in the MGIT 960 instrument (Becton Dickinson Diagnostic Systems, Sparks, MD). For cycloserine, the proportion method employed was modified according to Canetti \[[@r20]\]. In Romania, specimens were cultured on LJ medium. The proportion method was used to test isoniazid, rifampicin, ethambutol, streptomycin, kanamycin, amikacin, capreomycin, ofloxacin and ethionamide.

Genotyping
----------

On extracted genomic DNA from the mycobacterial strains, spoligotyping and 24-loci MIRU-VNTR was done following standard protocols \[[@r21],[@r22]\].

Whole genome sequencing and sequence data analysis
--------------------------------------------------

Libraries for sequencing were prepared from extracted genomic DNA with the Nextera XT library preparation kit and sequenced on the Illumina MiSeq next generation sequencing (NGS) platform in a 2 × 301 bp paired-end run (Illumina, San Diego, US).

WGS data of sequenced isolates were submitted to the EMBL-EBI ENA sequence read archive (accession number: ERP013444). Resulting reads were mapped to the *M. tuberculosis* H37Rv genome (GenBank accession number: NC_000962.3) with the SARUMAN exact alignment tool \[[@r23]\]. The mean genomic coverage was at least 45-fold, with more than 99% of the reference genome covered for all isolates. Variants were called from mapped reads by in-house Perl scripts, asking for a minimum coverage of 10 reads and a minimum allele frequency of 75% as detection thresholds. Combining detected single nucleotide polymorphisms (SNPs) of all isolates, positions that matched the threshold levels in at least 95% of all isolates were considered as valid and used for a concatenated sequence alignment excluding variants in resistance-associated or repetitive regions of the genome.

We employed the BioNumerics software (Applied Maths NV, Belgium) to build a neighbour-joining tree from the 708 concatenated SNP positions. Putative transmission groups were predicted with a cut-off of 12 distinct SNP positions (referred to as WGS~12SNPs~ clusters) \[[@r24]\].

All variants located on genes that were previously associated with mutations conferring drug resistance were extracted from the full set of detected variants, and the derived subset of variants was manually annotated with published data \[[@r8],[@r25]-[@r30]\].

WGS was performed at the NRL at the Research Center Borstel in Germany.

Epidemiological investigation
-----------------------------

We used a self-designed form in all three countries to systematically compile patient information, direct epidemiological links (exposure of at least 8 hours or at least 40 hours to, respectively, a sputum smear- or culture-positive but sputum smear-negative source case) \[[@r31],[@r32]\], and spatio-temporal information in terms of the patients' city and country of stay per month from January 2009 to July 2014. The data sources were records of the responsible authorities and re-interviews of the patients III, IV, V, VI. The others could not be contacted, had reportedly moved away or did not follow the invitation by the authorities.

We compiled these data into a line list using Microsoft Excel and analysed them descriptively.

Legal framework and data protection
-----------------------------------

Patient data had been collected as part of routine case notification and contact investigation according to the Tuberculosis Law (Tuberkulosegesetz) in Austria, Law Number 95/2006 on Health Reform in Romania, and the Protection against Infection Act (Infektionsschutzgesetz; IfSG) in Germany.

The collection of direct person-to-person links required international sharing of all patients' names. The Decision Number 1082/2013/EU of the European Parliament and of the Council \[[@r33]\] stipulates that proper authorities may communicate personal data for contact tracing purposes through selective exchanges in the European Early Warning and Response System (EWRS). In Germany, authorisation to collect personal data under the terms of section 16(1) IfSG lies with local public health authorities while the national authority's administrative involvement in handling personal data (section 25(1), IfSG) is restricted to international travellers (section 12(7) International Health Regulation Implementation Act).

Accordingly, in Germany, one of the responsible local authorities compiled the patients' names, assigned random unique identifiers (IDs) and redistributed the key to authorities in charge of the patients in the three countries. The form was completed using the ID, the key destroyed and anonymous data shared with the German national TB contact point at the Robert Koch Institute (RKI) for analysis.

The investigation protocol had been positively evaluated by data protection and legal departments of the RKI.

Results
=======

Austria
-------

In March 2014, *M. tuberculosis* (non-Beijing genotype) isolates from five MDR-TB patients in Austria were found to share the same spoligotype and 24-loci MIRU-VNTR pattern 'A'. Three patients (I--III) diagnosed from 2010 to 2012, originated from the same city in Romania ([Figure 1A](#f1){ref-type="fig"}, [Table 1](#t1){ref-type="table"}). They had moved to two different cities in Austria, seeking medical care for their complicated MDR-TB. Two patients (IV and V) had been diagnosed with new MDR-TB in June 2013. They were residents of the same Austrian city to which patients I and II had moved and had no history of migration or international travel.

![Cluster of multidrug-resistant tuberculosis in Austria, Romania and Germany, 2010 to 2014 (n = 13)](eurosurv-22-30439-f1){#f1}

###### Cluster of multidrug-resistant tuberculosis in Austria, Romania and Germany, demographic and clinical characteristics of the investigated patients, 2010 to 2014 (n = 13)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient ID   Country of residence at the beginning of the investigation   Sex      Age group (years)   Country of birth   Month and year of diagnosis of current episode   Previous TB\          Site of disease
                                                                                                                                                                             (year of diagnosis)   
  ------------ ------------------------------------------------------------ -------- ------------------- ------------------ ------------------------------------------------ --------------------- -----------------
  **I**        Austria                                                      Female   30--39              Romania            03/2010                                          Yes\                  Pulmonary
                                                                                                                                                                             (2001)                

  **II**       Austria                                                      Male     50--59              Romania            01/2011                                          No                    Pulmonary

  **III**      Austria                                                      Female   30--39              Romania            03/2012                                          Yes\                  Pulmonary
                                                                                                                                                                             (1998, 2003)          

  **IV**       Austria                                                      Male     40--49              Austria            06/2013                                          No                    Pulmonary

  **V**        Austria                                                      Male     50--59              Austria            06/2013                                          No                    Pulmonary

  **VI**       Germany                                                      Female   30--39              Romania            12/2011                                          No                    Pulmonary

  **VII**      Germany                                                      Female   30--39              Romania            05/2011                                          No                    Pulmonary

  **VIII**     Germany                                                      Male     30--39              Nigeria            07/2011                                          No                    Extrapulmonary

  **IX**       Romania                                                      Male     40--49              Romania            01/2004                                          No                    Pulmonary

  **X**        Romania                                                      Male     50--59              Romania            12/2011                                          Yes\                  Pulmonary
                                                                                                                                                                             (2011)                

  **XI**       Romania                                                      Male     30--39              Romania            01/2014                                          No                    Pulmonary

  **XII**      Romania                                                      Male     20--29              Romania            12/2013                                          No                    Pulmonary

  **XIII**     Romania                                                      Female   60--69              Romania            01/2014                                          Yes\                  Pulmonary
                                                                                                                                                                             (2004)                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ID: unique patient identifier; TB: tuberculosis.

Contact tracing did not confirm any epidemiological link between patients I to IV. However, a link between patients IV and V was assumed; they had both frequented the vicinity of the railway station and had problematic alcohol use.

Patient III reported having a sister diagnosed with MDR-TB living in Germany. This prompted the AGES to share the spoligotype and MIRU-VNTR pattern ([Table 2](#t2){ref-type="table"}) with Germany.

###### Cluster of multidrug-resistant tuberculosis in Austria, Romania and Germany, bacteriological confirmation and spoligotype and 24-loci MIRU-VNTR pattern of the isolates from the investigated patients, 2010 to 2014 (n = 13)

  ID     Bacterial confirmation           Archive run accession   Spoligotype                                   24-loci MIRU-VNTR                                                                                           
  ------ -------------------------------- ----------------------- --------------------------------------------- ------------------- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
  I      ND                               ERR1163047              1111111100111111111111111111111100001111111   2                   2   3   2   2   3   4   2   2   4   2   4   2   2   5   1   5   3   3   2   3   5   2   2
  II     Culture-pos, NAAT-pos, ssm-pos   ERR1163048              1111111100111111111111111111111100001111111   2                   2   3   2   2   3   4   2   2   4   2   4   2   2   5   1   5   3   3   2   3   5   2   2
  III    Culture-pos, NAAT-pos, ssm-pos   ERR1163049              1111111100111111111111111111111100001111111   2                   2   3   2   2   3   4   2   2   4   2   4   2   2   5   1   5   3   3   2   3   5   2   2
  IV     Culture-pos, NAAT-pos            ERR1163050              1111111100111111111111111111111100001111111   2                   2   3   2   2   3   4   2   2   4   2   4   2   2   5   1   5   3   3   2   3   5   2   2
  V      Culture-pos, NAAT-pos            ERR1163051              1111111100111111111111111111111100001111111   2                   2   3   2   2   3   4   2   2   4   2   4   2   2   5   1   5   3   3   2   3   5   2   2
  VI     Culture-pos, NAAT-pos, ssm-pos   ERR1163052              1111111100111111111111111111111100001111111   2                   2   3   2   2   3   4   2   2   4   2   4   2   2   5   1   5   3   3   2   3   5   2   2
  VII    Culture-pos, NAAT-pos, ssm-pos   ERR1163053              1111111100111111111111111111111100001111111   2                   2   3   2   2   3   4   2   2   4   2   4   2   2   5   1   5   3   3   2   3   5   2   2
  VIII   Microscopy of EP specimen-pos    ERR1163054              1111111100111111111111111111111100001111111   2                   2   3   2   2   3   4   2   2   4   2   4   2   2   5   1   5   3   3   2   3   5   2   2
  IX     Culture-pos                      ERR1163055              1111111100111111111111111111111100001111111   2                   2   3   2   3   3   3   2   2   4   2   4   2   2   5   1   5   3   3   2   3   5   2   2
  X      Culture-pos, ssm-pos             ERR1163056              1111111100111111111111111111111100001111111   2                   2   3   2   2   3   4   2   2   4   2   4   2   2   5   1   5   3   3   2   3   5   2   2
  XI     Culture-pos, ssm-pos             ERR1163057              1111111100111111111111111111111100001111111   2                   2   3   2   2   3   4   2   2   4   2   4   2   2   5   1   5   3   3   2   3   5   2   2
  XII    Culture-pos, ssm-pos             ERR1163058              1111111111111111111111111111111100001111111   2                   3   4   2   4   3   1   2   2   3   2   3   2   3   6   1   5   3   3   2   2   5   2   2
  XIII   Culture-pos, ssm-pos             ERR1163059              1111111111111111111111111111111100001111111   2                   3   4   2   4   3   1   2   2   3   2   3   2   3   6   1   5   3   3   2   2   5   2   2

ID: unique patient identifier; MIRU-VNTR ND: 24-loci mycobacterial interspersed repetitive units variable number of tandem repeats; no data; ssm: sputum smear microscopy; shaded cells: distinct molecular typing patterns.

Germany
-------

In early April, the NRL in Germany identified three isolates with MIRU-VNTR pattern 'A'. One isolate referred to the sister of patient III (patient VI), the second to another woman born in Romania (patient VII), and the third to a man born in West Africa with extrapulmonary non-MDR-TB (patient VIII; [Figure 1B](#f1){ref-type="fig"}).

As five patients (I--III, VI and VII) reportedly originated from the same city in Romania, the Romanian national TB contact point was informed. In mid-April 2014, all three countries held their first telephone conference and agreed upon a joint investigation.

Romania
-------

In Romania, in the absence of systematic MIRU-VNTR typing of MDR-TB strains, isolates from all five MDR-TB patients (IX--XIII) ever reported in the corresponding district were typed at the Austrian NRL. The isolate from patient IX had a unique MIRU-VNTR pattern 'B', the isolates from patients X and XI shared pattern 'A', and the ones from patients XII and XIII shared a distinct pattern 'C' and a different spoligotype ([Figure 1C](#f1){ref-type="fig"}, [Table 2](#t2){ref-type="table"}).

Epidemiological investigation
-----------------------------

Investigation forms were completed for patients II--XIII by seven public health authorities by September 2014. For patient I, only a laboratory report was available.

All patients were adults, five women and eight men; six had experienced migration (I--III and VI--VIII). Nine had new TB, four (I, III, X and XIII) had had previous TB, the first TB diagnosis dating back to year 1998 (III). All but patient VIII had pulmonary TB ([Table 1](#t1){ref-type="table"}).

The two sisters (III and VI) were confirmed to have a direct epidemiological link between them. Direct links were ruled out for persons II, III, IV, V, VII, IX and XII, and unknown for VI, VIII, X, XI and XIII. The assumed link between cases IV and V was negated when re-interviewing the persons ([Figure 1D](#f1){ref-type="fig"}).

The two sisters (III and VI) had crossed borders presumably while being infectious ([Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}). Other patients with migration background had moved before 2009 (II) or at an unknown date (I, VII, VIII). The mobility pattern did not preclude TB transmission events from patient II to patients IV and V in Austria, nor from patient III to patients X--XIII in Romania. The sisters III and VI had a space--time correlation in Romania in August 2011, however, only about one month before the beginning of the assumed infectious period of patient VI.

![Geographical dimension of the three WGS~12SNPs~ cluster of multidrug-resistant tuberculosis, Austria, Romania and Germany, 2010 to 2014 (n = 10)](eurosurv-22-30439-f2){#f2}

![Patient mobility per city/country and month, cluster of multidrug-resistant tuberculosis, Austria, Romania and Germany, 2010 to 2014 (n = 10)](eurosurv-22-30439-f3){#f3}

Whole genome sequencing
-----------------------

WGS was completed by August 2014. WGS~12SNPs~ divided cluster 'A' into two subgroups (one comprising patients II, IV, V and X, the other patients III, VI, VII and XI), and two separate cases (I and VIII). The third WGS~12SNPs~ cluster was congruent with genotyping pattern 'C' ([Figure 1E](#f1){ref-type="fig"}). The isolates from patients II and IV, as well as II and V were distinct by 3 and 4 SNPs, respectively. Isolates from patients XII and XIII were genetically identical (0 SNPs). The isolates from the epidemiologically linked sisters were distinct by 12 SNPs.

The first two WGS~12SNPs~ clusters spanned across borders, while the third was domestic ([Figure 2](#f2){ref-type="fig"}).

The detected mutations mediating resistance to first-line drugs correlated with phenotypic DST results. The isoniazid resistance-conferring mutation S315T in *katG* fully matched phenotypic isoniazid resistance; the same was observed for S450L or T400A in *rpoB* and rifampicin/rifabutin resistance and A146V in *pncA* and pyrazinamid resistance (information missing for patients IX--XIII). Two phenotypical ethambutol-susceptible isolates harboured the known resistance-mediating mutation M306I in *embB*; the resistant isolates showed either the mutation M306I or a combination of two mutations G406S and D1024N.

In addition, we detected resistance-mediating mutations for streptomycin (*rpsL* K43R) and kanamycin/amikacin (*rrs* 1401 A -\> G). One of two quinolone-resistant isolates shows a mutation in *gyrA* (A288D), a quinolone resistance-associated gene. Among the five isolates phenotypically resistant to ethionamide, one harboured a frameshift insertion in *ethA.* Four out of eight phenotypical protionamide-resistant isolates, showed frameshift insertions in *ethA* ([Tables 3](#t3){ref-type="table"} and [4](#t4){ref-type="table"}). Patients in one WGS cluster shared a cluster-specific set of resistance-mediating mutations, patient X in cluster 1 and patient VI in cluster 2 had acquired an additional aminoglycoside resistance (*rrs* 1401 A -\> G).

###### Phenotypic drug susceptibility testing results, cluster investigation of multidrug-resistant tuberculosis, Austria, Romania and Germany, 2010 to 2014 (n = 13)

  ID     H     R     Z     E     Eth   Pt    PAS   Rb    Cs    S     Amk   Kan   Cap   Ofl   Mox   Lev
  ------ ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  I      Res   Res   Res   Sus   ND    Res   Sus   Res   Sus   Sus   Sus   ND    Sus   Res   Res   ND
  II     Res   Res   Res   Res   ND    Res   Sus   Res   Sus   Res   Sus   ND    Sus   Sus   ND    ND
  III    Res   Res   Res   Res   Res   Res   Sus   Res   Res   Res   Sus   ND    Sus   Res   Res   Res
  IV     Res   Res   Res   Sus   ND    Res   Sus   Res   Sus   Res   Sus   ND    Sus   Sus   Sus   ND
  V      Res   Res   Res   Sus   Res   Res   Sus   Res   Sus   Res   Sus   ND    Sus   Sus   Sus   ND
  VI     Res   Res   Res   Res   Res   Res   Sus   Res   Sus   Res   Res   ND    Res   Sus   ND    ND
  VII    Res   Res   Res   Res   Res   Res   Sus   Res   Sus   Res   Sus   ND    Sus   Sus   ND    ND
  VIII   Res   Sus   Res   Sus   Res   Res   ND    ND    ND    Res   ND    ND    Sus   Sus   ND    ND
  IX     Res   Res   ND    ND    ND    ND    ND    ND    ND    Res   ND    ND    ND    ND    ND    ND
  X      Res   Res   ND    Res   Sus   ND    ND    ND    ND    Res   Res   Res   Res   Sus   ND    ND
  XI     Res   Res   ND    Res   Sus   ND    ND    ND    ND    Res   Sus   Sus   Sus   Sus   ND    ND
  XII    Res   Res   ND    Sus   Sus   ND    ND    ND    ND    Res   Sus   Sus   Sus   Sus   ND    ND
  XIII   Res   Res   ND    Sus   Sus   ND    ND    ND    ND    Res   Sus   Sus   Sus   Sus   ND    ND

Amk: amikacin; Cap: capreomycin; E: ethambutol; Eth: ethionamide; ID: unique patient identifier; Kan: kanamycin; Lev: levofloxacin; Mox: moxifloxacin; ND: no data; H: isoniazid; Ofl: ofloxacin; PAS: para-aminosalicylic acid; Pt: protionamide; R: rifampicin; Rb: rifabutin; Res: resistant; Cs: cycloserine; S: streptomycin; Sus: susceptible; Z: pyrazinamide.

###### Genotypic drug susceptibility testing results, cluster of multidrug-resistant tuberculosis, Austria, Romania and Germany, 2010 to 2014 (n = 13)

  ID     H           R           R           Z           E           E           E            Eth/Pt           Eth/Pt           Ami                S            SM        PAS        FQ
  ------ ----------- ----------- ----------- ----------- ----------- ----------- ------------ ---------------- ---------------- ------------------ ------------ --------- ---------- ----------
  I      S315T ^a^   WT          S450L ^a^   A146V ^a^   WT          WT          D1024N ^b^   WT               Ins 802 ag ^b^   WT                 Q125\_ ^b^   WT        R222C^b^   A288D^b^
  II     S315T ^a^   WT          S450L ^a^   A146V ^a^   M306I ^a^   WT          WT           Ins 1391 a ^b^   WT               WT                 Q125\_ ^b^   WT        WT         WT
  III    S315T ^a^   WT          S450L ^a^   A146V ^a^   WT          G406S^a^    D1024N ^b^   WT               WT               WT                 Q125\_ ^b^   WT        WT         WT
  IV     S315T ^a^   WT          S450L ^a^   A146V ^a^   M306I ^a^   WT          WT           Ins 1391 a ^b^   WT               WT                 Q125\_ ^b^   WT        WT         WT
  V      S315T ^a^   WT          S450L ^a^   A146V ^a^   M306I ^a^   WT          WT           Ins 1391 a ^b^   WT               WT                 Q125\_ ^b^   WT        WT         WT
  VI     S315T ^a^   WT          S450L ^a^   A146V ^a^   WT          G406S ^a^   D1024N ^b^   WT               WT               1401 A -\> G ^a^   Q125\_ ^b^   WT        WT         WT
  VII    S315T ^a^   WT          S450L ^a^   A146V ^a^   WT          G406S ^a^   D1024N ^b^   WT               WT               WT                 Q125\_ ^b^   WT        WT         WT
  VIII   S315T ^a^   WT          WT          A146V ^a^   WT          WT          WT           WT               WT               WT                 Q125\_ ^b^   WT        WT         WT
  IX     S315T ^a^   WT          S450L ^a^   A146V ^a^   M306I ^a^   WT          D1024N ^b^   WT               WT               WT                 Q125\_ ^b^   WT        WT         WT
  X      S315T ^a^   WT          S450L ^a^   A146V ^a^   M306I ^a^   WT          WT           Ins 1391 a ^b^   WT               1401 A- \> G ^a^   Q125\_ ^b^   WT        WT         WT
  XI     S315T ^a^   WT          S450L ^a^   A146V ^a^   WT          G406S ^a^   D1024N ^b^   WT               WT               WT                 Q125\_ ^b^   WT        WT         WT
  XII    S315T ^a^   T400A ^a^   S450L ^a^   WT          WT          WT          WT           WT               WT               WT                 WT           K43R^1^   WT         WT
  XIII   S315T ^a^   T400A ^a^   S450L ^a^   WT          WT          WT          WT           WT               WT               WT                 WT           K43R^1^   WT         WT

Ami: aminoglycoside; E: ethambutol; Eth: ethionamide; FQ: fluroquinolones; ID: unique patient identifier; H: isoniazid; PAS: para-aminosalicylic acid; Pt: protionamide; R: rifampicin; S: streptomycin; Z: pyrazinamide; WT: wild type.

^a^ resistance mediating mutation.

^b^ resistance associated variant.

Discussion
==========

We investigated a molecular cluster of MDR-TB in Austria, Romania and Germany. WGS combined with epidemiological information showed that isolates from patient II, seeking medical care in Austria, differed from the subsequently diagnosed Austrian patients IV and V by only 3 and 4 SNPs, respectively. This suggested that two MDR-TB transmission events had occurred in Austria. Isolates from patients III, VI, VII and XI, who lived in three different countries but had the same city of provenance, differed by 6--12 SNPs from each other. Here, transmission is likely to have occurred before the patients moved abroad.

Close genetic similarity of isolates from different patients is highly unlikely to occur by chance. From well-described TB outbreaks we know that isolates gained within three years from patients with a direct epidemiological link usually differ by 5 or fewer SNPs \[[@r34],[@r35]\]. In an outbreak of nine drug-susceptible TB cases in San Francisco, US, the isolates differed by 0--2 SNPs per any transmission event that had resulted in a secondary case \[[@r6]\]. In a similar investigation in Germany, differences of 0--3 SNPs were found (n = 31) \[[@r7]\]. From a retrospective study of TB outbreaks, Walker and colleagues derived that epidemiological linkage is expected to be consistent with sequenced isolates differing in up to 5 SNPs; the absence of an epidemiological link is consistent with more than 12 SNPs, while pairs of 6--12 SNPs were considered to be indeterminate \[[@r24]\].

In our investigation, isolates from the two epidemiologically linked sisters differed by 12 SNPs. This strongly suggests one or more missing links in the transmission chain, namely a common source case for both sisters with possibly additional intermediate cases. Missing links may be the result of undetected TB cases, the restriction of our investigation to only one district in Romania, unavailable genotyping results, or from selection based on identical MIRU-VNTR patterns when a mutation affected a VNTR locus even though isolates differed only by few SNPs \[[@r6]\].

We investigated a single scenario and may not draw conclusions about the extent of cross-border transmission of MDR-TB in the EU. The ECDC MDR-TB molecular surveillance project investigated 2,092 MIRU-VNTR patterns of isolates from 24 contributing EU Member States from 2003 to 2011 \[[@r19]\]. In total, 941 cases in 79 European multiple-country clusters were detected and 1,086 cases were allocated to national clusters. That study was solely based on genotyping data. In the UK, 24-loci MIRU-VNTR typing and epidemiological surveillance data were linked and jointly interpreted, and 8.5% of the MDR-TB cases were attributed to recent domestic transmission \[[@r36]\]. Similar nationwide evaluations are missing for our countries.

A high proportion of imported MDR-TB in low-incidence countries does not necessarily entail ongoing MDR-TB transmission when early case detection, infection control and adequate treatment succeed \[[@r19]\]. A systematic review for the EU/European Economic Area indicates that TB in the foreign-born population has no significant influence on TB in the native population \[[@r37]\].

Beyond higher resolution in TB outbreak investigation, WGS provided us in addition with information on drug resistance of the bacteria. We could identify mutations mediating pyrazinamide resistance in previously not tested isolates and mutations mediating ethambutol resistance in two samples with susceptible phenotypic DST results. However, our data on mutations mediating drug resistance to ethionamide, protionamide and the quinolones showed discrepancies between phenotypical and genotypical DST. A comprehensive database of characterised mutations is needed to extend the usability of WGS in predicting drug resistance, e.g. in order to provide rapid and effective treatment in outbreaks of drug-resistant TB. The concordance of resistance-mediating mutations in each WGS cluster confirmed transmission of MDR strains rather than treatment failure and new acquisition of MDR in each patient \[[@r10]\].

Our investigation was subject to limitations. The collection of direct epidemiological links yielded little information. It was difficult to differentiate whether a specific contact was absent (e.g. due to missing links), unknown (exposures in public space, recall bias) or non-reported (reluctance to name persons). Spatio-temporal data did not cover all patients' presumed infectious periods and travel history. Their low resolution (per city/country and month) allowed us to judge whether a contact was possible at all, but not to explore new exposure settings or events. More detailed investigations are difficult given long infectious periods and serial intervals in TB transmission chains.

The clinical characteristics 'cavitary disease' and 'HIV status' were not assessed as they are not notifiable everywhere, although relevant to assessing infectiousness and transmission risks. For patient I, it remained unclear which local public health authority was in charge. This highlights the challenge in transferring patient reports when patients are highly mobile.

We learned that the choice of methods and the order in which we use them can play a significant role. If WGS had been used initially and had led to the detection of the close genetic relationship between isolates from patients II, IV and V in Austria, a cross-border investigation might not have been initiated.

The cross-border investigation of a single genotyping cluster of TB can become complex and labour-intensive with uncertain public health benefits. In our case, there were no implications for contact tracing, which had already been completed. However, such investigation as ours may detect previously undetected individuals with TB. While investigations might get more efficient with increasing routine, each cluster brings together a new group of competent authorities that need to establish collaboration. Systematic and timely integration of genotyping and sequencing data into TB surveillance improves the understanding of transmission in a given country and internationally \[[@r38]\].

Topical issues remain: Should WGS replace 24-loci MIRU-VNTR as a standard? By when? How should we collect, analyse and interpret sequencing data within routine TB surveillance \[[@r39]\] and evaluate utility? How should we prioritise cluster investigations? Are there reliable predictors of cluster growth \[[@r40]-[@r43]\]? Will epidemiological links remain an essential component in TB outbreak definitions, i.e. may we use the term 'outbreak' solely based on WGS results when epidemiological links cannot confirmed? How can we collaborate most efficiently across borders when contact networks are complex and personal data are to be shared by everyone with everyone else? Could a secure interactive online platform complement communication channels such as EWRS?

Conclusion
==========

Our joint cross-border investigation clarified a transboundary MDR-TB transmission scenario. The applied methods complemented each other: genotyping results prompted our investigation, classic epidemiological data anchored the cluster in time and space, and WGS allowed a high resolution of transmission and new information on drug-resistance.

To prevent further MDR-TB transmission within and between countries, we need to ensure universal access to early and adequate therapy in order to reduce incentives to seek medical care abroad and to ensure infection control and seamless collaboration in TB care beyond administrative borders \[[@r44]\].
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